Biotronik Neuro Buys Spinal Cord Stim IP from Soin Neuroscience

Soin Neuroscience, a Dayton-Ohio-based company founded by pain management physician Dr. Amol Soin, revealed that it sold a portfolio of spinal cord stimulation (SCS) intellectual property to Biotronik Neuro.

The acquired patents cover tech in SCS waveform design, adaptive programming, and use of machine learning (ML) and artificial intelligence (AI) in neuromodulation therapy. Biotronik Neuro hopes to use the IP to eventually add a next-gen SCS program to its chronic pain portfolio.

Soin and Biotronik began assessing novel waveforms and personalized SCS tuning approaches on the latter’s Prospera SCS in December. The acquisition adds an IP repository of data-driven, adaptive stimulation to Biotronik’s platform that already features flexible programming and remote patient management.

Founder Dr. Soin is medical director of the Ohio Pain Clinic in Centerville. He’s built pain-focused innovations from the Dayton region, with a suite of patented neuromodulation technologies that aim to cut the reliance on opioids to treat chronic pain.

“This is a proud moment not just for our company, but for Dayton and Ohio’s life sciences community,” said Dr. Soin. “Innovation in medicine doesn’t have to come only from the coasts. We’ve built this technology here, and seeing it recognized by a company of BIOTRONIK’s caliber is validation of the work our team has put in over many years.”

“BIOTRONIK Neuro has the scale, engineering depth, and commitment to neuromodulation to take these technologies further than we could on our own,” he continued. “This agreement lets that work continue inside an organization built to bring it to patients at scale.

Soin Neuroscience will keep operating as an independent company—the transaction only covers the IP underlying the companies’ SCS program. The company will continue developing other pain management and medical technologies from its Dayton headquarters.

“Dr. Soin and his team have consistently pushed the boundaries of what personalized stimulation can look like, and this IP is a strong complement to our own SCS platform,” said Andreas Gute, president at Biotronik Neuro. “Bringing these patents into BIOTRONIK Neuro reflects the natural next step in our relationship and reinforces our commitment to advancing neuromodulation science for the benefit of patients living with chronic pain.”

The deal’s financial terms were not disclosed.